Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
3 Magnificent S&P 500 Dividend Stocks Down As Much As 36% to Buy and Hold Forever
There’s something oddly satisfying about snagging a great stock while it’s in the discount bin. I’ve always found this particularly true with dividend stocks - buying when they’re down means locking in higher yields for potentially decades to come. Let me share three S&P 500 dividend payers that have taken a serious beating but might deserve a permanent place in your portfolio.
1. Verizon Communications
Let’s be honest - Verizon isn’t going to make you rich through explosive growth. The wireless market is saturated to death with 98% of American adults already owning mobile phones, while landlines continue their slow march toward extinction.
But if immediate income is your game, Verizon’s 6.2% forward yield looks mighty tempting after the stock’s 30% decline from its 2019 peak. They’ve raised dividends for 18 straight years, and the $2.71 in annual payments is comfortably covered by expected earnings of $4.69 per share.
I’ll admit the $124 billion debt load makes me nervous - that’s nearly as much as their $136 billion annual revenue. But their consistent cash generation suggests they can handle these obligations, and let’s face it - Americans would sooner give up food than their smartphones at this point.
2. Accenture
Accenture might be the $158 billion giant you’ve never heard of. Despite generating $65 billion in revenue last year and $7.7 billion in profits, it operates largely behind the scenes.
What makes Accenture interesting is its hybrid business model. Half comes from one-off consulting gigs, but the other half is recurring “managed services” revenue - essentially companies outsourcing their complex ongoing operations to Accenture. This creates the predictable cash flow that dividend investors crave.
So why has the stock plunged 36% since February? Market paranoia about tariffs and rising rates potentially squeezing corporate budgets for Accenture’s services. Yet revenue still grew 8% last quarter, and analysts expect similar growth next year.
The 2.3% yield might seem modest, but the dividend has grown a staggering 85% in just five years. I’d rather have a smaller yield that doubles every few years than a stagnant higher one.
3. Lockheed-Martin
Defense contractor Lockheed has had a rough year, with shares down 26% since October. Much of this stems from reduced F-35 fighter jet orders from both the Pentagon and international allies due to performance issues and eye-watering costs.
But I think the market is overreacting. The F-35 represents less than a third of Lockheed’s revenue, and much of that comes from maintenance contracts that continue regardless of new sales. Meanwhile, their other weapons systems are seeing booming demand - the Army recently allocated $5 billion for Lockheed’s precision strike missiles, and they received an additional $2 billion for high-altitude defense interceptors.
The company still expects $74 billion in revenue this year, up from last year’s $71 billion, with similar growth projected next year. Their 2.9% dividend yield has increased for 22 consecutive years.
The market will eventually recognize that a few canceled fighter jets don’t outweigh Lockheed’s overall strong position in an increasingly unstable world. I wouldn’t wait too long on this one.
Disclaimer: For information purposes only. Past performance is not indicative of future results.